Stock Ratings / Health Care / CRDF / dividends

GRML (32) CGTX (43) NMRA (42) CSBR (22) ⌘ Pro Terminal →

Cardiff Oncology Inc. (CRDF) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.89 -2.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.88

Cardiff Oncology Inc. (CRDF) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $70.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRDF Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRDF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Cardiff Oncology Inc. (NASDAQ: CRDF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.89 (-2.46% 1D, market cap $70.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRDF ranks #509 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRDF compare to GRML and CGTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDF carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRML (Greenland Mines Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, CRDF leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRDF?

▼

Per CRDF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213037), Cardiff Oncology Inc. generated $593.0K in revenue (-13.2% YoY), -$45.9K in net income, and -$38.0M in free cash flow against $61.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.88 (-0.63%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRDF)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY CRDF SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (37% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 38.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.08-16.7% Next Q

Q2 (-2Q)

Grade D$0.90+1.1% Next Q

Q3 (-1Q)

Grade D$0.91-2.2% Next Q

Current

Grade D-$0.89-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRDF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRDF currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.08) and Max Pain ($0.93) forces dealer call-delta covering toward $3.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRDF• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRDF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRDF)

✓Walkthrough of CRDF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRDF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.55%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.90H $0.92L $0.86C $0.89VOL 126.9K

RES: $1.57SUP: $0.77SMA50: $1.08SMA200: $1.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRDF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRDF Butterfly Map → + Track CRDF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -13.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRDF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRDF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRDF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRDF)

Health Care Rank #509 of 1016 ⚔️ GRML vs CRDF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRDF vs. GRML, CGTX, NMRA, CSBR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardiff Oncology Inc. (CRDF) ranks #509 by composite RQD confidence (41/100, grade D-) and #705 by equity capitalization ($70.9M). Within this direct 5-issuer industry benchmark cohort, CRDF leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CRDF at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRDF ACTIVE Cardiff Oncology Inc.	D-	41/100	—	—	-35.0%	-2.46%	$70.9M	Benchmark Subject
GRML Greenland Mines Ltd.	E	32/100	—	—	-35.0%	-10.89%	$70.3M	/grml-vs-crdf →
CGTX Cognition Therapeutics Inc.	D-	43/100	—	—	-35.0%	-5.57%	$70.3M	/cgtx-vs-crdf →
NMRA Neumora Therapeutics Inc.	D-	42/100	—	—	-35.0%	-5.43%	$73.0M	/nmra-vs-crdf →
CSBR Champions Oncology Inc.	E	22/100	—	48.0%	-26.9%	0.00%	$66.9M	/csbr-vs-crdf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213037

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cardiff Oncology Inc. (CRDF) reported GAAP revenue of $593.0K (-13.2% vs. FY2024 revenue of $683.0K , and +21.5% cumulative change since FY2023) , GAAP net income of -$45.9K, operating cash flow of -$37.9M, and free cash flow of -$38.0M (-0.5% YoY). On the balance sheet, CRDF closed FY2025 with $61.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$593.0K	-$45.9K	-$37.9M	-$38.0M	$61.9M	—
FY2024 (FY)	2024-12-31	$683.0K	-$45.4K	-$37.7M	-$37.8M	$97.2M	—
FY2023 (FY)	2023-12-31	$488.0K	-$41.4K	-$30.9M	-$30.9M	—	—

3. CRDF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRDF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRDF compare to GRML and CGTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRDF?

Where is CRDF trading relative to its 50-day, 200-day, and 52-week technical levels?

CRDF last traded at $0.89 (-2.46% on volume of 126,880 shares), positioning the stock -17.59% below its 50-day simple moving average ($1.08) and -38.19% below its 200-day simple moving average ($1.44). Across its 52-week range of $0.76 to $3.31, CRDF sits at the 5.1% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.00).

CRDF Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CRDF pay a dividend and is it safe?

Cardiff Oncology Inc. (CRDF) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CRDF RQD Cockpit CRDF 12M Forecast CRDF Earnings & Move CRDF Dividends & DRIP CRDF Insiders & 13F CRDF Whale Options CRDF Profit Sankey CRDF News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRDF — Cardiff Oncology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:45:37Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CRDF scores 41/100 with a letter grade of D- and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 5/20. Return on invested capital is -35% and FCF yield is 0%. For an investor, this indicates the business is not currently generating returns on the capital it deploys, so value would depend on future developments rather than present cash generation.
Whale 13F Flow: 15/20. The rating cites institutional accumulation and options positioning. This is the strongest pillar, suggesting some institutional interest, though the source data does not itemize holders (see Analyst View section).
Insider Conviction: 3/20. The rating cites SEC Form 4 and Congressional PTR cluster flow at a low score, which an investor should read as limited insider-side confidence signals.
Macro Regime Fit: 11/20. Beta is 1.0 and the rating notes sector sensitivity. The stock moves in line with the broad market on this measure, with no defensive cushion indicated.
Forensic Balance Sheet: 7/20. Altman Z-Score is 2.5, Piotroski F-Score is 1 of 9, and Debt/Equity is 0.5. The weak Piotroski reading points to poor financial-health signals across the nine tests.

Upside drivers in the data are limited to the pipeline and institutional interest; the valuation tradeoff is that a $70.9M market capitalization with negative operating margin (-60%) and negative ROIC leaves little earnings support for the current price. The rating's overall posture is cautious.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.6M	$-49.0M	$-0.0M	N/A	$-38.0M	$17.5M	N/A
FY 2024	$0.7M	$-48.7M	$-0.0M	N/A	$-37.8M	$51.5M	N/A
FY 2023	$0.5M	$-45.4M	$-0.0M	N/A	$-30.9M	N/A	N/A

Per the SEC financials, operating losses are consistently large relative to revenue, and the operating margin is -60%. Net margin is -7.7% and gross margin is 0%. ROIC is -35%. Cash declined from $51.5M in FY 2024 to $17.5M in FY 2025, a reduction of $34.0M in one year. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, per the Roarable RQD rating. The Debt/Equity ratio is 0.5; the debt line itself is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the following items are listed:

Trial and management update (YELLOW): Reporting states that all trial patients still enrolled have received more than 18 months of treatment, and that the company named an interim medical chief.
Earnings preview (YELLOW): A TradingView item references a Q3'26 EPS estimate of (0.14) USD.
Q2 2026 earnings (RED, Risk Watch): An item describes a narrower-than-expected loss while advancing the clinical-stage pipeline.
Share authorization (YELLOW): Holders approved doubling authorized common stock to 300 million shares. This is a potential dilution consideration.
Price action (YELLOW): One report describes shares sliding 7.21% to $0.90 and testing a lower support zone; the current market data shows a price of 0.89 and a change of -2.2%.
Forecast article (YELLOW): A StockInvest.us item discusses market action and institutional positioning.

The Butterfly supply-chain graph lists no links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and bottlenecks are not available in source data. The most relevant second-order consideration visible in the data is the approved increase in authorized shares to 300 million, which a prospective investor could track for dilution effects on per-share value given the $0.89 price and $70.9M market capitalization.

Open Questions

What is the company's cash runway given cash of $17.5M at FY 2025 against FCF of -$38.0M?
What is the debt balance behind the reported Debt/Equity of 0.5, and what are the maturities?
What specific clinical programs drive the pipeline, and what are their timelines and milestones?
What is the source and magnitude of the institutional accumulation cited in the whale-flow pillar?
How will the approved increase to 300 million authorized shares affect outstanding shares and dilution?

CRDF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cardiff Oncology Inc. (CRDF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRDF Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 7h ago

Cardiff Oncology Stock Price Forecast. Should You Buy CRDF?

StockInvest.us report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 10h ago

All trial patients still enrolled have had over 18 months of treatment. Cardiff Oncology names an interim medical chief.

Stock Titan report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 13h ago

CRDF Q3'26 Earnings: EPS estimate is (0.14) USD

TradingView report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 16h ago

Cardiff Oncology Inc. (CRDF) Slides 7.21% to $0.90 as Shares Test Lower Support Zone - Bollinger Expansion

https://www.siam.in/ report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 19h ago

CRDF Q2 2026 Earnings: Narrower-Than-Expected Loss as Cardiff Oncology Advances Clinical-Stage Pipeline - Guidance Accuracy Score

https://www.dars.gov.et/ report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Minichart • 22h ago

Cardiff Oncology Holders Approve Doubling Authorized Common Stock to 300 Million Shares

Minichart report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Cardiff Oncology, Inc. (CRDF) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Cardiff Oncology, Inc. Stock Price Today | CRDF Live Chart & News

Traders Union report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRDF Bull vs. Bear Conversation Board — What's Your Call at $0.89?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRDF 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.78 (-12.4%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CRDF (D- • RQD 41/100) a Buy at $0.89?

Welcome to the CRDF (Cardiff Oncology Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.67 (-24.7%)

Spot @ $0.89

Pump the brakes on CRDF — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CRDF, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cardiff Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.14 (+28.1%)

Spot @ $0.89

CRDF cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CRDF, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.89 (52-wk range $0.76 - $3.31), any beat on forward guidance forces shorts and underweight funds to chase.